Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: When is the optimal time for stem cell harvest?

Thomas Elmer Witzig, Morie Gertz, John A. Lust, Robert A. Kyle, Philip R. Greipp

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

This study serially quantitated monoclonal plasma cells (PC) in the peripheral blood (PB) of 33 patients with multiple myeloma (MM) at diagnosis, after therapy, and at relapse using a sensitive immunofluorescence technique. The goal was to learn which disease phase is best for harvesting PB stem cells free of monoclonal PC. In 24 chemotherapy responders, 88% (21/24) had circulating PC at diagnosis; after therapy, 63% (15/24) had none, 33% (8/24) had <3 × 106/L, and only one had ≥3 × 106/L. In nine cases who failed to respond to initial chemotherapy, 89% (8/9) had high levels (≥3 × 106/L) of circulating PC at diagnosis that remained high after therapy. In the relapse phase, 88% (21/24) had circulating PC and 63% (15/24) had high numbers. This study demonstrates that the PB is least likely to have circulating monoclonal PC during the period after successful chemotherapy. Patients who fail to respond to initial chemotherapy or are in relapse are likely to have tumor cells in the PB.

Original languageEnglish (US)
Pages (from-to)417-422
Number of pages6
JournalLeukemia and Lymphoma
Volume19
Issue number5-6
DOIs
StatePublished - 1995

Fingerprint

Plasma Cells
Multiple Myeloma
Blood Cells
Stem Cells
Drug Therapy
Recurrence
Fluorescent Antibody Technique
Therapeutics
Neoplasms

Keywords

  • Bone marrow transplant
  • Multiple myeloma
  • Stem cells

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Serial studies of peripheral blood myeloma cells in patients with multiple myeloma : When is the optimal time for stem cell harvest? / Witzig, Thomas Elmer; Gertz, Morie; Lust, John A.; Kyle, Robert A.; Greipp, Philip R.

In: Leukemia and Lymphoma, Vol. 19, No. 5-6, 1995, p. 417-422.

Research output: Contribution to journalArticle

@article{45c82925e67c4df08e6c7c64fec3df40,
title = "Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: When is the optimal time for stem cell harvest?",
abstract = "This study serially quantitated monoclonal plasma cells (PC) in the peripheral blood (PB) of 33 patients with multiple myeloma (MM) at diagnosis, after therapy, and at relapse using a sensitive immunofluorescence technique. The goal was to learn which disease phase is best for harvesting PB stem cells free of monoclonal PC. In 24 chemotherapy responders, 88{\%} (21/24) had circulating PC at diagnosis; after therapy, 63{\%} (15/24) had none, 33{\%} (8/24) had <3 × 106/L, and only one had ≥3 × 106/L. In nine cases who failed to respond to initial chemotherapy, 89{\%} (8/9) had high levels (≥3 × 106/L) of circulating PC at diagnosis that remained high after therapy. In the relapse phase, 88{\%} (21/24) had circulating PC and 63{\%} (15/24) had high numbers. This study demonstrates that the PB is least likely to have circulating monoclonal PC during the period after successful chemotherapy. Patients who fail to respond to initial chemotherapy or are in relapse are likely to have tumor cells in the PB.",
keywords = "Bone marrow transplant, Multiple myeloma, Stem cells",
author = "Witzig, {Thomas Elmer} and Morie Gertz and Lust, {John A.} and Kyle, {Robert A.} and Greipp, {Philip R.}",
year = "1995",
doi = "10.3109/10428199509112199",
language = "English (US)",
volume = "19",
pages = "417--422",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - Serial studies of peripheral blood myeloma cells in patients with multiple myeloma

T2 - When is the optimal time for stem cell harvest?

AU - Witzig, Thomas Elmer

AU - Gertz, Morie

AU - Lust, John A.

AU - Kyle, Robert A.

AU - Greipp, Philip R.

PY - 1995

Y1 - 1995

N2 - This study serially quantitated monoclonal plasma cells (PC) in the peripheral blood (PB) of 33 patients with multiple myeloma (MM) at diagnosis, after therapy, and at relapse using a sensitive immunofluorescence technique. The goal was to learn which disease phase is best for harvesting PB stem cells free of monoclonal PC. In 24 chemotherapy responders, 88% (21/24) had circulating PC at diagnosis; after therapy, 63% (15/24) had none, 33% (8/24) had <3 × 106/L, and only one had ≥3 × 106/L. In nine cases who failed to respond to initial chemotherapy, 89% (8/9) had high levels (≥3 × 106/L) of circulating PC at diagnosis that remained high after therapy. In the relapse phase, 88% (21/24) had circulating PC and 63% (15/24) had high numbers. This study demonstrates that the PB is least likely to have circulating monoclonal PC during the period after successful chemotherapy. Patients who fail to respond to initial chemotherapy or are in relapse are likely to have tumor cells in the PB.

AB - This study serially quantitated monoclonal plasma cells (PC) in the peripheral blood (PB) of 33 patients with multiple myeloma (MM) at diagnosis, after therapy, and at relapse using a sensitive immunofluorescence technique. The goal was to learn which disease phase is best for harvesting PB stem cells free of monoclonal PC. In 24 chemotherapy responders, 88% (21/24) had circulating PC at diagnosis; after therapy, 63% (15/24) had none, 33% (8/24) had <3 × 106/L, and only one had ≥3 × 106/L. In nine cases who failed to respond to initial chemotherapy, 89% (8/9) had high levels (≥3 × 106/L) of circulating PC at diagnosis that remained high after therapy. In the relapse phase, 88% (21/24) had circulating PC and 63% (15/24) had high numbers. This study demonstrates that the PB is least likely to have circulating monoclonal PC during the period after successful chemotherapy. Patients who fail to respond to initial chemotherapy or are in relapse are likely to have tumor cells in the PB.

KW - Bone marrow transplant

KW - Multiple myeloma

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=0028791787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028791787&partnerID=8YFLogxK

U2 - 10.3109/10428199509112199

DO - 10.3109/10428199509112199

M3 - Article

C2 - 8590841

AN - SCOPUS:0028791787

VL - 19

SP - 417

EP - 422

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -